Abstract
The increasing prevalence of poorly soluble active pharmaceutical ingredients（APIs）in development provides notable risk of new products demonstrating low and erratic bioavailability with consequences for safety and efficacy, particularly for drugs delivered by not only the oral route of administration, but also parenteral administration. In addition, biotechnology has revolutionized science and health care by providing new biomolecules with biological and medical applications. However, the low stability of several life-saving bioproducts still hinders their transport, storage, and application. Herein we summarized recent developments in the area of ionic liquids（ILs）that are being used as improving the solubility of API and stabilizer of protein-based products.
